Kintara Therapeutics Inc (KTRA) has released an update.
Kintara Therapeutics and TuHURA Biosciences have announced a definitive all-stock merger to create a new entity focused on developing advanced cancer treatments, including a personalized cancer vaccine and antibody drug conjugates. The merger is backed by a $31 million financing deal and aims to leverage both companies’ technologies to address resistance to cancer immunotherapy, a significant unmet medical need. The newly formed company, which will be named TuHURA Biosciences and trade under the ticker ‘HURA’, is expected to enhance shareholder value and extend its financial runway into late 2025.
For further insights into KTRA stock, check out TipRanks’ Stock Analysis page.
